Control of the transition to long-term nonprogressor in tristable HIV dynamics

The human immunodeficiency virus (HIV) infection, that causes acquired immune deficiency syndrome (AIDS), is a dynamic process that can be modeled via differential equations. In this paper we apply a control strategy to boost the immune response for a tristable HIV dynamic model. The purpose of this control method is to steer the system to an equilibrium condition known as long-term nonprogressor, which corresponds to an infected patient that does not develop the symptoms of AIDS. The control strategy is implemented by controlled drug scheduling based on the understanding of the immune boosting mechanism. The feasibility of the methodology is illustrated via simulations.

[1]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[2]  Robert F. Stengel,et al.  Optimal enhancement of immune response , 2002, Bioinform..

[3]  Hyungbo Shim,et al.  A system theoretic study on a treatment of AIDS patient by achieving long-term non-progressor , 2009, Autom..

[4]  H. Chang,et al.  An Application of Gradual Reduction of Drug Dose to HIV Infection Model in Consideration of Drug Resistance and Drug Dose , 2006, 2006 SICE-ICASE International Joint Conference.

[5]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[6]  R. D. de Boer,et al.  Role of avidity and breadth of the CD4 T cell response in progression to AIDS , 2006, Proceedings of the Royal Society B: Biological Sciences.

[7]  A. Astolfi,et al.  Control of HIV Infection Dynamics by the Enhancement of the Immune System , 2008 .

[8]  Hyungbo Shim,et al.  Control of immune response of HIV infection model by gradual reduction of drug dose , 2004, 2004 43rd IEEE Conference on Decision and Control (CDC) (IEEE Cat. No.04CH37601).

[9]  Hyeygjeon Chang,et al.  Control of HIV Infection Dynamics , 2008, IEEE Control Systems.

[10]  Alessandro Astolfi,et al.  Control of HIV Infection Dynamics Control of HIV Infection Dynamics , 2008 .

[11]  B. Walker,et al.  Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes , 2003, The Journal of experimental medicine.

[12]  Alessandro Astolfi,et al.  Activation of Immune Response in Disease Dynamics via Controlled Drug Scheduling , 2009, IEEE Transactions on Automation Science and Engineering.

[13]  B. Adams,et al.  HIV dynamics: Modeling, data analysis, and optimal treatment protocols , 2005 .

[14]  D. Wodarz,et al.  Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. , 2001, Journal of theoretical biology.

[15]  H. K. Altes,et al.  The race between initial T–helper expansion and virus growth upon HIV infection influences polyclonality of the response and viral set–point , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[16]  Chung Choo Chung,et al.  Optimal Scheduling of Drug Treatment for HIV Infection : Continuous Dose Control and Receding Horizon Control , 2003 .

[17]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[18]  Martin A Nowak,et al.  Virus evolution within patients increases pathogenicity. , 2005, Journal of theoretical biology.

[19]  G. Carcelain,et al.  Boosting Immunity to HIV--Can the Virus Help? , 2000, Science.

[20]  Leading to Long-Term Nonprogressor via Gradual Reduction of Drug Dose with Immune Dynamics Strongly Dependant on Target Cells , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[21]  Ryan Zurakowski,et al.  A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.

[22]  J. Lisziewicz,et al.  Control of HIV despite the discontinuation of antiretroviral therapy. , 1999, The New England journal of medicine.

[23]  M. Nowak,et al.  Specific therapy regimes could lead to long-term immunological control of HIV. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Philip J. R. Goulder,et al.  HIV and SIV CTL escape: implications for vaccine design , 2004, Nature Reviews Immunology.